| Document |
Document Title |
|
WO/2024/056091A1 |
The present invention relates to a pyridonopyrimidine derivative as an RSK protein kinase inhibitor and use thereof. Specifically, the present invention relates to a compound represented by formula I, a pharmaceutical composition compris...
|
|
WO/2024/022365A1 |
The present invention relates to a Wnt pathway inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inf...
|
|
WO/2024/008097A1 |
A compound represented by formula (I) or an isomer, a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof. The compound is a PROTAC molecule having excellent degradation activity on a CDK protein kinase, lays a s...
|
|
WO/2024/006879A1 |
Provided herein are inhibitors of ubiquitin-specific-processing Protease 1 (USP1), their pharmaceutical compositions, and methods of use for treating diseases or disorders, such as cancers described herein.
|
|
WO/2023/215367A1 |
Provided herein are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, R1, R2, R3, and n are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a comp...
|
|
WO/2023/143501A1 |
Provided are a compound possessing the structure of formula (I) and having excellent Wnt pathway inhibitory activity, or a pharmaceutically acceptable salt, an isotope derivative, or a stereoisomer thereof. Further provided are a prepara...
|
|
WO/2023/126297A1 |
The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combi...
|
|
WO/2023/078426A1 |
Provided in the present invention are a compound, a pharmaceutical composition containing same, and the use thereof. The compound interferes with the interaction between the menin protein and MLL1 or MLL2 or a MLL fusion oncoprotein, and...
|
|
WO/2023/061437A1 |
The present invention relates to a salt of an antitumor drug and a crystal form thereof, and specifically relates to a pharmaceutical salt of the compound N-(3-(2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-
7-oxo-6-phenyl-8(7H)-...
|
|
WO/2023/059583A1 |
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC ...
|
|
WO/2023/046114A1 |
Disclosed in the present invention is a compound as represented by formula I or a pharmaceutically acceptable salt thereof. Such compounds exhibit an excellent effect of targeted inhibition of non-canonical mutations of EGFR and have a g...
|
|
WO/2023/028054A1 |
Described herein are inhibitors of EGFR exon 20 insertion mutants and methods of treating cancer comprising the administration of said inhibitors.
|
|
WO/2023/028022A1 |
A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical compo...
|
|
WO/2023/016134A1 |
A compound of general formula (I) containing a tetrahydropterin structure, and a preparation method therefor and a use thereof. A composition containing the compound of general formula (I) or a pharmaceutically acceptable salt thereof an...
|
|
WO/2023/005894A1 |
An inhibitor compound as represented by formula (I) for a Wnt pathway and a pharmaceutical composition containing same, and the use of the compound as represented by the formula (I) for preventing and/or treating cancers, tumors, inflamm...
|
|
WO/2023/284747A1 |
The present application discloses a novel use of an EGFR inhibitor. The EGFR inhibitor is a compound N-(3-(2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-
7-oxo-6-phenyl-8(7H)-pteridyl)phenyl)acrylamide, which may be used in the p...
|
|
WO/2022/268180A1 |
Provided is a compound as represented by formula (I), or a prodrug, a tautomer, a stereoisomer, a solvate, an isotope derivative, or a pharmaceutically acceptable salt thereof. The compound has a relatively strong MAT2A inhibitory effect...
|
|
WO/2022/272307A1 |
The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface receptor, such as a folate receptor. The cell surface folate binding compound can trigger the receptor to internaliz...
|
|
WO/2022/272313A1 |
Small molecules compounds and methods of their synthesis are provided. Small molecules identified can inhibit histone acetyltransferase 1 activty. Formulations and medicaments are also provided that are directed to the treatment of human...
|
|
WO/2022/268167A1 |
The present invention relates to a medicine for treating xerophthalmia and a method for improving wearing experience of people with contact lens discomfort, and further relates to a therapeutic eye drop.
|
|
WO/2022/261770A1 |
The present invention relates to a combination comprising a neurotensin receptor binding compound and FOLFIRINOX for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.
|
|
WO/2022/260545A1 |
The subject of the invention is a new methotrexate-glucose conjugate derivative, its synthesis, and its use in the treatment and prevention of neoplasms, preferably in the treatment and prevention of neoplasms selected from: skin cancer,...
|
|
WO/2022/236272A2 |
The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of ...
|
|
WO/2022/206730A1 |
A new compound which effectively inhibits MAT2A, and which is a compound represented by formula III, or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound represented by formula III: ,...
|
|
WO/2022/194166A1 |
The use of a methotrexate analogue in the treatment of an inflammatory skin disease. The methotrexate analogue not only has a strong activity and low toxicity and low side effects, but can also target skin in a distributed manner so as t...
|
|
WO/2022/175222A1 |
The present invention relates to cryptophycin compounds, to new cryptophycin payloads, to new cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents.
|
|
WO/2022/096015A1 |
A method for preparing a 3,6-diaminopyrazine-2,5-dicarboxylic acid and a synthetic intermediate thereof. The method comprises the step of preparing pyrimido[4,5-g]pteridine-2,4,7,9 (1H,3H,6H,8H)-tetrone or a disalt (pteridine) thereof fr...
|
|
WO/2022/008419A1 |
The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combi...
|
|
WO/2021/261062A1 |
Provided is an aqueous solution having, dissolved therein, 0.3 to 200 mM of a stilbene compound (A) that is a compound represented by formula (1) or a glycoside thereof and 0.3 to 200 mM of a flavin derivative (B) selected from riboflavi...
|
|
WO/2021/249558A1 |
The present invention relates to a pteridone derivative as an RSK protein kinase inhibitor and an application thereof. Specifically, the present invention relates to a compound represented by formula I, a pharmaceutical composition compr...
|
|
WO/2021/244555A1 |
Disclosed are a compound intermediate material for synthesizing a chiral drug and a preparation method for the compound intermediate material. The intermediate for synthesis disclosed in the present invention has a low production cost, s...
|
|
WO/2021/221097A1 |
Provided are: a novel compound, and a pharmaceutically acceptable salt thereof, represented by formula (1), the compound having a histamine H4 receptor-regulating effect and being useful in the treatment and/or prevention of an illness o...
|
|
WO/2021/203673A1 |
The present application provides a nitrogen containing compound, an organic electroluminescent device using same, and an electronic device. A chemical structure of an organic compound in the present invention comprises a carbazole ring. ...
|
|
WO/2021/163727A1 |
The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.
|
|
WO/2021/133144A1 |
The present invention relates to: a novel organic electron transfer mediator which shows an excellent oxidation-reduction potential; and a device comprising same, such as an electrochemical biosensor, which has improved performance.
|
|
WO/2021/123116A1 |
The present invention relates to a compound represented by the following formula (I): A[B-(C)v]w, wherein A is a photoprotective moiety, B is a linker, C is a functional group, v is an integer from 1 to 2000, and w is an integer from 1 t...
|
|
WO/2021/112661A1 |
The present invention relates to a process for obtaining polymer nanoparticles stabilised with a non-ionic polymer surfactant functionalised with a ligand, for receptor-mediated drug delivery. The distinctive feature of the invention is ...
|
|
WO/2021/072269A1 |
The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can b...
|
|
WO/2020/239953A1 |
The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3 (hereinafter P2X3 inhibitors); particularly the invention relates to compounds that are pyridopyrimidines derivatives, methods of preparing such compou...
|
|
WO/2020/201724A1 |
The disclosure provides a tracer composition. The composition comprises a fluorescent molecule which fluoresces when exposed to an excitation wavelength, and thereby emit a photon with a wavelength between 400 and 600 nm; and a gelling a...
|
|
WO/2020/172664A1 |
Described herein are genetic recognition reagents that bind specifically to a target nucleic acid and comprise terminal left-handed PNA cooperative binding domains that enable concatenation of two or more of the recognition reagents when...
|
|
WO/2020/156017A1 |
The present invention relates to a compound represented by formula (I) or a tautomer, optical isomer, deuterated substance, oxynitride, solvate, pharmaceutically acceptable salt or prodrug thereof, a preparation method for the compound, ...
|
|
WO/2020/156437A1 |
The present invention discloses an AKT inhibitor, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. The present invention further provides a preparation method thereof, and the...
|
|
WO/2020/142612A1 |
Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmace...
|
|
WO/2020/140055A1 |
Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are u...
|
|
WO/2020/089443A1 |
The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected...
|
|
WO/2020/092375A1 |
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes...
|
|
WO/2020/083089A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a polymorph, a tautomer, an isotope compound, and a metabolite or a prodrug thereof for treating diseases that ...
|
|
WO/2020/078455A1 |
The present invention relates to a structurally novel TLR8 (Toll-like receptor 8) agonist and, in particular, to a compound thereof of formula (I), a pharmaceutically acceptable salt and an isomer thereof.
|
|
WO/2020/073906A1 |
Disclosed is a kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also disclosed are a pharmaceutical composition comprising the kinase inhi...
|
